Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Bukwang Pharmaceutical Dividend Announcement
• Bukwang Pharmaceutical announced a annually dividend of ₩100.00 per ordinary share which will be made payable on 2022-04-11. Ex dividend date: 2021-12-29
• Bukwang Pharmaceutical's trailing twelve-month (TTM) dividend yield is -%
Bukwang Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2021-12-29 | ₩100.00 | annually | 2022-04-11 |
2020-12-29 | ₩90.91 | annually | 2021-04-09 |
2019-12-27 | ₩173.16 | annually | 2020-03-31 |
2018-12-27 | ₩200.00 | annually | 2019-03-29 |
2017-12-27 | ₩220.00 | annually | 2018-03-30 |
2016-12-28 | ₩600.00 | annually | |
2015-12-29 | ₩700.00 | annually | |
2014-12-30 | ₩500.00 | annually | |
2014-12-29 | ₩500.00 | annually | |
2013-12-27 | ₩500.00 | annually | |
2012-12-27 | ₩430.00 | annually | |
2011-12-28 | ₩210.00 | annually | |
2011-03-30 | ₩500.00 | annually | |
2010-03-30 | ₩500.00 | annually |
Bukwang Pharmaceutical Dividend per year
Bukwang Pharmaceutical Dividend growth
Bukwang Pharmaceutical Dividend Yield
Bukwang Pharmaceutical current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Bukwang Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Bukwang Pharmaceutical Financial Ratios
Bukwang Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Bukwang Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Bukwang Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Bukwang Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Bukwang Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Bukwang Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Bukwang Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Bukwang Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Bukwang Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Bukwang Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Bukwang Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Bukwang Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.